FDA Clears Guayama Manufacturing Facility
This article was originally published in The Pink Sheet Daily
You may also be interested in...
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
Lybrel To Launch In July Following FDA Approval
Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.